$6.51
▲ +2.5% Today
as of Aug 5, 16:52 ET
Last 30 days
Recent Press Releases & News
Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
Overview
52-week range
$1.57
$9.75
60% of range
Avg surprise (last 3)
-30.6%
Avg reaction (last 2)
-2.1%
0% positive
Latest IV / EM
141%
EM ±23.5% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $0.01 | $0.12 | -91.7% | +106.2% | -1.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.16 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.17 | $-0.17 | 0.0% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.16 | $-0.16 | 0.0% | — | -2.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.89 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.09 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.09 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | BMO | -$0.14 | -$0.17 | +17.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83M | — | $13M | $5M | $3M | — | $727,000 | $1M |
| Cost of revenue | — | — | $3M | $3M | $2M | — | $2M | $1M |
| Gross profit | — | — | $10M | $2M | $990,000 | — | $-788,000 | $88,000 |
| Operating income | $4M | — | $-56M | $-64M | $-59M | — | $-48M | $-470M |
| Net income | $5M | — | $-56M | $-59M | $-53M | — | $-41M | $-462M |
| EPS (diluted) | $0.01 | — | $-0.16 | $-0.17 | $-0.16 | — | $-0.15 | $-1.89 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $125M | $164M | $99M | $248M | $48M | $36M | $30M | $34M |
| Inventory | $16M | $11M | $6M | $552,000 | $14,000 | $0 | — | — |
| Total current assets | $592M | $572M | $578M | $623M | $476M | $526M | $565M | $587M |
| Total assets | $610M | $595M | $602M | $647M | $492M | $541M | $572M | $595M |
| Long-term debt | $47M | — | $47M | $47M | — | — | — | — |
| Total liabilities | $291M | $289M | $276M | $274M | $73M | $77M | $69M | $63M |
| Total equity | $320M | $306M | $326M | $373M | $419M | $464M | $503M | $257M |